Quanterix To Report Third Quarter 2024 Financial Results on November 12, 2024

QTRX 11.05.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:Quanterix Conference Call
Full Press ReleaseSEC FilingsOur QTRX Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - Quanterix to Present at 43rd Annual J.P. Morgan Healthcare Conference
  • 01.14.2025 - Quanterix Provides Update on Financial Performance
  • 01.10.2025 - Quanterix Corporation to Acquire Akoya Biosciences

Recent Filings

  • 01.17.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.16.2025 - 425 Prospectuses and communications, business combinations
  • 01.16.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
PDF Version

BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 5, 2024--Quanterix Corporation(NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call onTuesday, November 12, 2024, at4:30 p.m. E.T., to discuss third quarter 2024 financial results.

Quanterixwill issue a press release regarding third quarter 2024 financial results prior to the conference call onTuesday, November 12, 2024, after the market closes. The press release will be posted on theQuanterixwebsite athttps://www.quanterix.com/.

To pre-register for the conference call with a webcast linkclick here. For audio use the following dial-in number and passcode:USA&Canada- Toll-Free (800) 715-9871 Conference ID: 2720617. Interested investors can also access the live webcast from theNews & Eventspage within the Investors section of theQuanterixwebsite athttp://www.quanterix.com. An archived webcast replay will be available on the Company’s website for one year.

AboutQuanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa®technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease.Quanterixhas been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,100 peer-reviewed journals. Find additional information about theBillerica, Massachusetts-based company athttps://www.quanterix.comor follow us onTwitterandLinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with theU.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law,Quanterixassumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241105557132/en/

Media:Marissa Klaassen(978) 488-1854media@quanterix.com

Investor Relations:Amy Achorn(978) 488-1854ir@quanterix.com

Source:Quanterix Corporation

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com